Latest Breaking News On - Announces first patient - Page 1 : comparemela.com

[December 29, 2020] VBL Therapeutics Announces First Patient in Europe in the OVAL Trial Expands OVAL Phase 3 Potential Registration Study of VB-111 for the Treatment of Platinum-Resistant Ovarian Cancer into Europe  TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) VBL Therapeutics (Nasdaq: VBLT) today announced the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer into Europe, where the first patient has now been enrolled. The study continues to actively recruit patients in the U.S. and Israel, with over 200 patients enrolled to date. “VB-111 is our proprietary anti-cancer gene therapy product candidate that has shown overall survival benefit across multiple tumor types,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. “We are pleased to expand the OVAL potential registration study of VB-111 in patients with late stage ovarian cancer to E

Irina kofflerDror haratsExchange commissionData safety monitoring committeeVascular biogenics ltdEuropean commissionFoundation incAnnounces first patientRegistration studyPlatinum resistant ovarian cancerChief executive officerOrphan designationBiogenics ltdஇரினா கோஃப்லர்பரிமாற்றம் தரகுதகவல்கள் பாதுகாப்பு கண்காணிப்பு குழு